Development and validation of a risk score to predict QT interval prolongation in hospitalized patients

Circulation: Cardiovascular Quality and Outcomes

Volumn 6, Issue 4, 2013, Pages 479-487

  Tisdale, James E ^a,b   Jaynes, Heather A ^a   Kingery, Joanna R ^c   Mourad, Noha A ^a   Trujillo, Tate N ^c   Overholser, Brian R ^a,b   Kovacs, Richard J ^b,d  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY HEALTH   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Electrocardiography; Predictors; QT interval; Risk factors; Torsades de pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIINFECTIVE AGENT; POTASSIUM; PSYCHOTROPIC AGENT;

AGED; ARTICLE; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POTASSIUM BLOOD LEVEL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; QUANTITATIVE ANALYSIS; RISK FACTOR; RISK REDUCTION; RISK SCORE DEVELOPMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; TERTIARY HEALTH CARE;

ELECTROCARDIOGRAPHY; PREDICTORS; QT INTERVAL; RISK FACTORS; TORSADES DE POINTES;

AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CORONARY CARE UNITS; DECISION SUPPORT TECHNIQUES; FEMALE; HOSPITALIZATION; HUMANS; INDIANA; LOGISTIC MODELS; LONG QT SYNDROME; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TERTIARY CARE CENTERS; TORSADES DE POINTES;

EID: 84884492481     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.113.000152     Document Type: Article

References (25)

1. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153:891-899.
2. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM. Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J. 1984;107:425-430.
3. Tisdale JE. Ventricular arrhythmias. In: Tisdale JE, Miller DA. Drug-Induced Diseases. Prevention, Detection and Management. 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists; 2010:485-515.
4. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W; American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology; Council on Cardiovascular Nursing; American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55:934-947.
5. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent GM, Garson A Jr. The long QT syndrome: prospective longitudinal study of 328 families. Circulation. 1991;84:1136-1144.
6. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med. 1998;339:960-965.
7. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088-1093.
8. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993;269:1532-1536.
9. De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, Hoes AW. In-hospital cardiac arrest is associated with use of nonantiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol. 2007;63: 216-223.
10. Tisdale JE, Wroblewski HA, Overholser BR, Kingery JR, Trujillo TN, Kovacs RJ. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf. 2012;35:459-470.
11. Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, Liu J-N, Drew BJ. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study. Crit Care Med. 2012;40:394-399.
12. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;22:39-43.
13. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003;82:282-290.
14. CredibleMeds powered by AZCERT.ORG. http://www.azcert.org/medical-pros/ drug-lists/drug-lists.cfm. Accessed 2008.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
16. Bazett H. An analysis of the time-relationships of electrocardiograms. Heart. 1920;7:35-70.
17. Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom MC, Stricker BH, Witteman JC. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362-367.
18. Varriale P, Ramaprasad S. Septic cardiomyopathy as a cause of long QT syndrome. J Electrocardiol. 1995;28:327-329.
19. Sharkey SW, Shear W, Hodges M, Herzog CA. Reversible myocardial contraction abnormalities in patients with an acute noncardiac illness. Chest. 1998;114:98-105.
20. Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005;4:1.
21. Charbit B, Alvarez JC, Dasque E, Abe E, Démolis JL, Funck-Brentano C. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology. 2008;109:206-212.
22. Hreiche R, Plante I, Drolet B, Morissette P, Turgeon J. Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IKr blockers. J Pharm Sci. 2011;100:2469-2481.
23. Chézalviel-Guilbert F, Deplanne V, Davy JM, Poirier JM, Xia YZ, Cheymol G, Weissenburger J. Combination of sotalol and quinidine in a canine model of torsades de pointes: no increase in the QTrelated proarrhythmic action of sotalol. J Cardiovasc Electrophysiol. 1998;9:498-507.
24. Darpö B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 2001;3 suppl. K: K70-80.
25. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, Rodriguez Chavez L, Iturralde Torres P, Cruz FFE, Centurión OA, Fujiki A, Maury P, Chen X, Krahn AD, Roithinger F, Zhang L, Vincent GM, Zeltser D. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm. 2005;2:569-574.